Generic Medicine Info
Should be taken with food. Take shortly after a meal or a light snack.
Acute MI. Concomitant use or within 14 days of discontinuing MAOI(s). Children. Concomitant use with linezolid or IV methylene blue.
Special Precautions
Patient with history of suicide-related events; bipolar disorder, CV disease (e.g. previous MI, stroke, tachycardia, conduction abnormalities); risk factors for narrow-angle glaucoma; conditions which may predispose to priapism (e.g. sickle-cell anaemia, multiple myeloma, leukaemia); risk or history of seizures, head trauma, brain damage, alcoholism; hyperthyroidism, micturition disorder (e.g. prostate hypertrophy), hypokalaemia or hypomagnesaemia. Hepatic and renal impairment. Elderly. Pregnancy and lactation. Avoid abrupt withdrawal and dose reduction. Patient Counselling This drug may cause drowsiness, sedation, dizziness, confusional states, and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for clinical worsening, behavioural changes and emergence of suicidal thoughts. Monitor LFT prior to initiation of therapy and periodically thereafter.
Adverse Reactions
Significant: Suicidal ideation and behaviour, cardiac arrhythmia (e.g. QT interval prolongation, ventricular tachycardia); increased risk of bleeding, CNS depression, fall, osteoporotic fracture, narrow-angle glaucoma, orthostatic hypotension, syncope, priapism, activation of mania/hypomania, withdrawal syndrome, hyponatraemia. Cardiac disorders: Palpitation, bradycardia, tachycardia. Ear and labyrinth disorders: Tinnitus. Eye disorders: Ocular pruritus, blurred vision. Gastrointestinal disorders: Dry mouth, taste changes, flatulence, nausea, vomiting, constipation, diarrhoea, dyspepsia, stomach pain, gastroenteritis. General disorders and administration site conditions: Perspiration, oedema, influenza-like symptoms. Metabolism and nutrition disorders: Weight gain, anorexia, increased hunger. Musculoskeletal and connective tissue disorders: Asthenia, limb pain, back pain. Nervous system disorders: Dizziness, drowsiness, headache, tremor. Psychiatric disorders: Nervousness, expressive aphasia, confusional state, disorientation, mania, agitation, aggressive reaction, hallucinations. Respiratory, thoracic and mediastinal disorders: Nasal/sinus congestion. Skin and subcutaneous tissue disorders: Skin rash, pruritus. Vascular disorders: Hypertension.
Potentially Fatal: Haemorrhage, serotonin syndrome, severe hepatic failure.
Drug Interactions
Increased plasma concentration and increased risk of adverse effect with potent CYP3A4 inhibitor (e.g. itraconazole, clarithromycin). Increased risk of cardiac arrhythmia with drugs that can prolong QT interval (e.g. Class 1A/3 antiarrhythmics, chlorpromazine, gatifloxacin). Decreased concentration with CYP3A4 inducers (e.g. carbamazepine, phenytoin).
CIMS Class
Antidepressants / Anxiolytics
ATC Classification
N06AX05 - trazodone ; Belongs to the class of other antidepressants.
Disclaimer: This information is independently developed by CIMS based on trazodone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in